Spanish pharma company Reig Jofre’s (BME: RJF) share price rocketed 32% to 4.99 euros this morning, after it revealed that it has reached an agreement with Johnson & Johnson (NYSE: JNJ) subsidiary Janssen to execute the technology transfer to manufacture its investigational COVID-19 vaccine candidate, Ad26.COV2-S.
Reig Jofre’s long standing, widely recognized experience in the manufacturing of sterile injectable products, together with the availability of a state-of-the-art new Plant in Barcelona scheduled to come on-stream in the first quarter of 2021, create a unique opportunity to contribute to the need for a fast and secure deployment of the COVID-19 vaccine candidate.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze